Linical Co., Ltd.
Tokyo Stock Exchange 2183.T
Linical Co., Ltd. Free Cash Flow for the year ending March 31, 2024: USD 6.82 M
-
Linical Co., Ltd. Free Cash Flow for the year ending March 31, 2023 was USD 13.75 M, a 5.56% change year over year.
-
Linical Co., Ltd. Free Cash Flow for the year ending March 31, 2022 was USD 13.02 M, a 3,312.76% change year over year.
-
Linical Co., Ltd. Free Cash Flow for the year ending March 31, 2021 was USD -405.37 K, a -104.11% change year over year.
-
Linical Co., Ltd. Free Cash Flow for the year ending March 31, 2020 was USD 9.86 M, a 228.16% change year over year.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
Don’t Miss A Beat
| CEO | Mr. Kazuhiro Hatano |
| IPO Date | Oct. 27, 2008 |
| Location | Japan |
| Headquarters | Shin-Osaka Brick Building |
| Employees | 662 |
| Sector | Health Care |
| Industries | |
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Past 5 years
USD 6.79
USD 7.15
USD 9.48
StockViz Staff
January 30, 2025
Any question? Send us an email